SCHEMBL19355281

SCHEMBL19355281

CNC(=O)c1ccnc2c(CCNc3cc(-c4ccc(C#N)cc4)ncn3)cccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.45
CYP3A4 P08684 12/20 0.45
CYP2C19 P33261 11/20 0.45
CLK4 Q9HAZ1 10/20 0.45
ALDH1A1 P00352 9/20 0.45
CYP2D6 P10635 8/20 0.45
USP2 O75604 7/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
FAAH O00519 3/20 0.44
MAPK1 P28482 4/20 0.40
TSHR P16473 3/20 0.40
CDK1 P06493 1/20 0.39
ALOX15 P16050 3/20 0.38
CYP2C9 P11712 1/20 0.38
HSD17B10 Q99714 7/20 0.38
MAPT P10636 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
SLC40A1 Q9NP59 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19819890 0.90 CYP1A2 (0.45) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355128 0.90 CYP1A2 (0.41) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355476 0.90 FAAH (0.42) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355460 0.90 CYP1A2 (0.44) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355473 0.88 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355266 0.88 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19819904 0.88 CYP1A2 (0.41) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19905041 0.88 CYP1A2 (0.38) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19355284 0.87 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1
SCHEMBL19905362 0.87 CYP1A2 (0.41) CYP1A2CYP3A4CYP2C19CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057959-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2018-02-28 EP disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK CYP1A2 2215/4885CYP3A4 1759/4885CYP2C19 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.